Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5523455 | 1.00 | KDM4E (0.38) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL10326343 | 0.92 | TACR1 (0.37) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL15281108 | 0.91 | TACR1 (0.38) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL15248772 | 0.91 | TACR1 (0.38) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL14365129 | 0.91 | TACR1 (0.38) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL10326849 | 0.86 | KDM4E (0.43) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL10326340 | 0.85 | CYP1A2 (0.41) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL3006875 | 0.84 | TACR1 (0.41) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL1262080 | 0.84 | TACR1 (0.41) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL1262083 | 0.84 | TACR1 (0.41) | KDM4ENPC1CYP1A2CYP2D6HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190981-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION | 2010-07-29 | — | — | US | claimed |
| US-20250340559-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE HOLDINGS CORP (US) | 2025-11-06 | — | — | US | disclosed |
| US-12247030-B2 | Process for preparing compositions comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidine | INCYTE HOLDINGS CORPORATION (US) | 2025-03-11 | — | — | US | disclosed |
| EP-4501410-A2 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | Incyte Holdings Corporation (US) | 2025-02-05 | — | — | EP | disclosed |
| CN-119306753-A | Methods for preparing JAK inhibitors and related intermediate compounds | 因西特控股公司 | 2025-01-14 | — | — | CN | disclosed |
| EP-3272738-B1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE HOLDINGS CORP (US) | 2024-11-13 | — | — | EP | disclosed |
| CN-108395433-B | Methods for preparing JAK inhibitors and related intermediate compounds | 因西特控股公司 | 2024-10-22 | — | — | CN | disclosed |
| US-20210253584-A1 | Processes for Preparing Jak Inhibitors and Related Intermediate Compounds | INCYTE HOLDINGS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10975085-B2 | Process for preparing a composition comprising an enantiomeric excess of greater than or equal to 90% of the (R)-enantiomer of a compound of formula III | INCYTE HOLDINGS CORPORATION (US) | 2021-04-13 | — | — | US | disclosed |
| US-10364248-B2 | Processes for preparing 4-chloro-7H-pyrrolo[2,3-d]pyrimidine | INCYTE CORPORATION (US) | 2019-07-30 | — | — | US | disclosed |
| US-20130253191-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130253193-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION (US) | 2013-09-26 | — | — | US | disclosed |
| US-8410265-B2 | Processes for preparing JAK inhibitors and related intermediate compounds | INCYTE CORPORATION (US) | 2013-04-02 | — | — | US | disclosed |
| US-8217204-B2 | Catalyst for asymmetric hydrogenation | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| EP-2398774-A2 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | Incyte Corporation (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-12-23 | — | — | US | disclosed |
| WO-2010140636-A1 | ASYMMETRIC HYDROGENATION CATALYST | 高砂香料工業株式会社 (JP) | 2010-12-09 | — | — | WO | disclosed |
| US-20100190981-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION | 2010-07-29 | — | — | US | disclosed |
| WO-2010083283-A2 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION (US) | 2010-07-22 | — | — | WO | disclosed |
| US-20070276142-A1 | Catalytic Asymmetric Synthesis of Optically Active Alpha-Halo-Carbonyl Compounds | CHEMINOVA A/S (DK) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | H1-0, H1-5, ADH5 | KDM4E 4195/4885NPC1 2005/4885CYP1A2 1183/4885 |
| US-12247030-B2 | Process for preparing compositions comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidine | DPYD, TYMS, TYMP | KDM4E 2606/4885NPC1 4109/4885CYP1A2 297/4885 |
| US-10975085-B2 | Process for preparing a composition comprising an enantiomeric excess of greater than or equal to 90% of the (R)-enantiomer of a compound of formula III | JAK1, JAK3, JAK2 | KDM4E 754/4885NPC1 4213/4885CYP1A2 553/4885 |
| US-20130253193-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | KDM4E 1425/4885NPC1 4219/4885CYP1A2 1133/4885 |
| US-20210253584-A1 | Processes for Preparing Jak Inhibitors and Related Intermediate Compounds | JAK3, JAK1, JAK2 | KDM4E 1425/4885NPC1 4219/4885CYP1A2 1133/4885 |
| US-20070276142-A1 | Catalytic Asymmetric Synthesis of Optically Active Alpha-Halo-Carbonyl Compounds | CBR1, CBR3, HAO1 | KDM4E 3878/4885NPC1 1457/4885CYP1A2 55/4885 |
| US-10364248-B2 | Processes for preparing 4-chloro-7H-pyrrolo[2,3-d]pyrimidine | JAK1, JAK3, JAK2 | KDM4E 543/4885NPC1 4597/4885CYP1A2 982/4885 |
| US-20100190981-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | KDM4E 1425/4885NPC1 4219/4885CYP1A2 1133/4885 |
| US-20250340559-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | KDM4E 1425/4885NPC1 4219/4885CYP1A2 1133/4885 |
| US-20130253191-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | KDM4E 1425/4885NPC1 4219/4885CYP1A2 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.